Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Director | June 18, 2026 | June 23, 2026 |
| BORGWARNER INCBWA · Entity 3425 | Director | April 29, 2020 | May 01, 2020 |
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | February 01, 2021 | February 04, 2021 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | January 02, 2025 | January 03, 2025 |
| REVVITY, INC.PKI · Entity 3382 | Director | February 09, 2017 | February 10, 2017 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 11, 2019 | June 12, 2019 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | May 01, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 95,400 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 95,400 · Balance 95,400 F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.
BORGWARNER INC
Report date April 29, 2020 · Filed May 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,823.19 |
Reported balance
After 2020-04-29 transaction · row 1
1 source rowRow 1 · 2020-04-29 · Grant · Acquired 4,382 · Balance 19,823.19 F1: The shares will vest 100% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest 100% on the first anniversary of the grant date.
BRISTOL MYERS SQUIBB CO
Report date February 01, 2021 · Filed February 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 75,689.427 |
Reported balance
After 2021-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-01 · Grant · Acquired 3,054.171 · Balance 75,689.427 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Denali Therapeutics Inc.
Report date January 02, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,976 |
Reported balance
After 2025-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-02 · Sale · Disposed 3,080 · Balance 107,976 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024. F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.75 to $21.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3: Includes 5,967 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.75 to $21.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 5,967 unvested RSUs.
REVVITY, INC.
Report date February 09, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,970 |
Ending reported balance
After 2017-02-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-02-09 · Exercise / conversion · Acquired 8,308 · Balance 38,278 Row 2 · 2017-02-09 · Sale · Disposed 8,308 · Balance 29,970 |
| NQ Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.36 · Expires 2017-05-11 | Direct | 0 |
Reported balance
After 2017-02-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-09 · Exercise / conversion · Disposed 8,308 · Balance 0 F1: This option became exercisable in three equal annual installments beginning on May 11, 2011, which was the first anniversary of the date on which the option was granted, and had a 7 year exercise term. |
Filing footnotes · ownership attribution and instrument terms
F1: This option became exercisable in three equal annual installments beginning on May 11, 2011, which was the first anniversary of the date on which the option was granted, and had a 7 year exercise term.
Syros Pharmaceuticals, Inc.
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2029-06-10 | Direct | 11,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 11,000 · Balance 11,000 F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.
Vir Biotechnology, Inc.
Report date May 01, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,078,391 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Sale · Disposed 22,000 · Balance 1,078,391 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akouos, Inc.
Report date December 01, 2022 · Filed December 02, 2022
Section 16 reporting ended · disclosed 2022-12-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.38 · Expires 2030-05-11 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-01 · Disposition to issuer · Disposed 26,930 · Balance 0 F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2] F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.38 · Expires 2030-05-11 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-01 · Disposition to issuer · Disposed 12,100 · Balance 0 F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2] F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2032-06-22 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-01 · Disposition to issuer · Disposed 16,000 · Balance 0 F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2] F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. |
Filing footnotes · ownership attribution and instrument terms
F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]
F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.
VERTEX PHARMACEUTICALS INC / MA
Report date May 11, 2005 · Filed May 12, 2005
Section 16 reporting ended · disclosed 2005-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,233 |
Ending reported balance
After 2005-05-11 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2005-05-11 · Exercise / conversion · Acquired 7,000 · Balance 115,108 Row 2 · 2005-05-11 · Sale · Disposed 7,000 · Balance 108,108 F1: Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1. Row 3 · 2005-05-11 · Disposition to issuer · Disposed 2,000 · Balance 106,108 F2: Restricted Shares repurchased by the Company pursuant to a Severance Agreement and Release dated February 7, 2005. Row 4 · 2005-05-11 · Disposition to issuer · Disposed 28,875 · Balance 77,233 F2: Restricted Shares repurchased by the Company pursuant to a Severance Agreement and Release dated February 7, 2005. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2005-12-13 | Direct | 910,655 |
Reported balance
After 2005-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2005-05-11 · Exercise / conversion · Disposed 7,000 · Balance 910,655 F3: Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995. F4: Reflects option to purchase 61,164 shares of common stock cancelled by the Company pursuant to a Severance Agreement and Release dated February 7, 2005. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 8,084 |
Reported balance
Holding disclosure · report date 2005-05-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 8,084 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1.
F2: Restricted Shares repurchased by the Company pursuant to a Severance Agreement and Release dated February 7, 2005.
F3: Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995.
F4: Reflects option to purchase 61,164 shares of common stock cancelled by the Company pursuant to a Severance Agreement and Release dated February 7, 2005.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2021 Filed Sep 17, 2021 20:04 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 230 | $52.28 | $12,024.40 |
DisclosureSEC source: 0001714899-21-000091 · wf-form4_163190905888608.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,935 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $51.56 to $52.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 9,045 | $45.52 | $411,728.40 |
DisclosureSEC source: 0001209191-21-052964 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,611,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.10 to $45.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,129 | $44.36 | $271,882.44 |
DisclosureSEC source: 0001209191-21-052964 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,620,833 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 21:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 860 | $52.12 | $44,823.20 |
DisclosureSEC source: 0001714899-21-000083 · wf-form4_162949494285003.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,165 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $51.86 to $52.395 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 21:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 806 | $51.26 | $41,315.56 |
DisclosureSEC source: 0001714899-21-000083 · wf-form4_162949494285003.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,025 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $50.79 to $51.77 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:37 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 31,692 | $0.00 Strike: $21.95 | $0.00 |
DisclosureSEC source: 0001214659-21-008125 · marketforms-53499.xml · derivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,692 Underlying: Common Stock · 31,692 shares Expires 2031-07-30 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in a series of 36 successive equal monthly installments measured from the date of grant. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:37 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 19,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-008125 · marketforms-53499.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,362 Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 21:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 400 | $65.78 | $26,312.00 |
DisclosureSEC source: 0001714899-21-000060 · wf-form4_162707596730665.xml · nonDerivative · entry 3 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,831 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $65.63 to $66.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 21:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 866 | $65.24 | $56,497.84 |
DisclosureSEC source: 0001714899-21-000060 · wf-form4_162707596730665.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,231 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $64.61 to $65.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 21:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 400 | $64.25 | $25,700.00 |
DisclosureSEC source: 0001714899-21-000060 · wf-form4_162707596730665.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,097 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $63.60 to $64.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 6,363 | $37.84 | $240,786.74 |
DisclosureSEC source: 0001209191-21-047505 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,626,962 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.30 to $38.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 8,811 | $36.74 | $323,722.31 |
DisclosureSEC source: 0001209191-21-047505 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,633,325 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.11 to $37.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 16:35 UTC | Akouos, Inc. AKUS · Entity 11574 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001104659-21-085758 · tm2120686-3_4seq1.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-06-23 F1 · derivative.exercise_date: This option was granted on June 24, 2021. The shares underlying the option will fully vest on the earlier of (i) June 24, 2022 and (ii) the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 20:51 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 986 | $71.11 | $70,109.53 |
DisclosureSEC source: 0001209191-21-043062 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,497 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $70.80 to $71.40 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 20:51 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 680 | $70.20 | $47,735.32 |
DisclosureSEC source: 0001209191-21-043062 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,483 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $69.74 to $70.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 23:57 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,293 | $46.75 | $153,945.12 |
DisclosureSEC source: 0001209191-21-042578 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,642,136 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.545 to $47.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 23:57 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 11,881 | $46.00 | $546,569.96 |
DisclosureSEC source: 0001209191-21-042578 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,645,429 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.43 to $46.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:36 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 6,222 | $0.00 Strike: $63.76 | $0.00 |
DisclosureSEC source: 0001209191-21-038389 · doc4.xml · derivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 Underlying: Common Stock · 6,222 shares Expires 2031-06-02 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:36 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 2,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038389 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,163 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 40 | $66.72 | $2,668.60 |
DisclosureSEC source: 0001209191-21-036513 · doc4.xml · nonDerivative · entry 3 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $66.60 to 66.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 732 | $65.88 | $48,220.50 |
DisclosureSEC source: 0001209191-21-036513 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,129 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $65.60 to $66.53 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 894 | $64.90 | $58,022.39 |
DisclosureSEC source: 0001209191-21-036513 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,861 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $64.58 to $65.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 6,748 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001209191-21-035702 · doc4.xml · derivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,748 Underlying: Common Stock · 6,748 shares Expires 2031-05-20 Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 3,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035702 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,657,310 Read SEC document |
| May 19, 2021 Filed May 20, 2021 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,443 | $44.96 | $64,877.28 |
DisclosureSEC source: 0001209191-21-034665 · doc4.xml · nonDerivative · entry 3 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,653,936 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $45.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 19, 2021 Filed May 20, 2021 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,403 | $44.18 | $238,704.54 |
DisclosureSEC source: 0001209191-21-034665 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,655,379 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 19, 2021 Filed May 20, 2021 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 8,328 | $43.35 | $361,018.80 |
DisclosureSEC source: 0001209191-21-034665 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,660,782 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.77 to $43.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 21:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 688 | $63.03 | $43,367.39 |
DisclosureSEC source: 0001209191-21-029337 · doc4.xml · nonDerivative · entry 3 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,755 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $62.73 to 63.27 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 21:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 597 | $62.05 | $37,042.06 |
DisclosureSEC source: 0001209191-21-029337 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,443 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $61.47 to $62.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 21:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 381 | $60.71 | $23,128.99 |
DisclosureSEC source: 0001209191-21-029337 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,040 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $60.36 to $60.985 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:47 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 136 | $57.61 | $7,834.42 |
DisclosureSEC source: 0001209191-21-024126 · doc4.xml · nonDerivative · entry 4 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,421 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.525 to $57.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:47 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 635 | $56.92 | $36,144.84 |
DisclosureSEC source: 0001209191-21-024126 · doc4.xml · nonDerivative · entry 3 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,557 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.52 to $57.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:47 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 877 | $55.91 | $49,033.95 |
DisclosureSEC source: 0001209191-21-024126 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,192 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.485 to $56.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:47 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 18 | $54.38 | $978.84 |
DisclosureSEC source: 0001209191-21-024126 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,069 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 23:04 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 115 | $63.37 | $7,286.98 |
DisclosureSEC source: 0001209191-21-017970 · doc4.xml · nonDerivative · entry 4 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,087 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 23:04 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 266 | $62.29 | $16,569.14 |
DisclosureSEC source: 0001209191-21-017970 · doc4.xml · nonDerivative · entry 3 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,202 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $62.18 to $63.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 23:04 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,050 | $61.52 | $64,600.20 |
DisclosureSEC source: 0001209191-21-017970 · doc4.xml · nonDerivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,468 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $61.14 to $61.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 23:04 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 235 | $60.36 | $14,184.60 |
DisclosureSEC source: 0001209191-21-017970 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,518 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.02 to $60.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: The Reporting Person reported a prior award of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 3,253 previously reported restricted stock units. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:19 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,054.171 | $62.21 | $189,999.98 |
DisclosureSEC source: 0000014272-21-000055 · wf-form4_161239794822236.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,689.427 Underlying: Common Stock, $0.10 par value · 3,054.171 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034772 · doc4.xml · derivative · entry 2 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,253 Underlying: Common Stock · 3,253 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F3 · derivative.expiration_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 15,183 | $0.00 Strike: $28.82 | $0.00 |
DisclosureSEC source: 0001209191-20-034772 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,183 Underlying: Common Stock · 15,183 shares Expires 2030-06-02 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 28,888 | $0.00 Strike: $37.06 | $0.00 |
DisclosureSEC source: 0001209191-20-032059 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,888 Underlying: Common Stock · 28,888 shares Expires 2030-05-21 Read SEC document |
| May 21, 2020 Filed Oct 13, 2020 23:14 UTC Amendment | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 23,649 | $0.00 Strike: $37.06 | $0.00 |
DisclosureSEC source: 0001209191-20-054741 · doc4a.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,649 Underlying: Common Stock · 23,649 shares Expires 2030-05-20 Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:03 UTC | BORGWARNER INC BWA · Entity 3425 | GrantCommon Stock | 4,382 | $29.67 | $130,013.94 |
DisclosureSEC source: 0001225208-20-006959 · doc4.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,823.19 F1 · shares: The shares will vest 100% on the first anniversary of the grant date. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 23:09 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,018.268 | $62.95 | $189,999.97 |
DisclosureSEC source: 0000014272-20-000067 · wf-form4_158085771887023.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,459.893 Underlying: Common Stock, $0.10 par value · 3,018.268 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 23:40 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 22,222 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053066 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,222 Underlying: Common Stock · 22,222 shares Expires 2029-10-10 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on October 10, 2020, and the remainder vest in 24 equal monthly installments thereafter. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 20:16 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantCommon Stock (right to buy) · Derivative | 11,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-19-036364 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| May 30, 2019 Filed May 31, 2019 22:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 27,245 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001209191-19-033743 · doc4.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,245 Underlying: Common Stock · 27,245 shares Expires 2029-05-29 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date. Read SEC document |
| April 24, 2019 Filed May 8, 2019 19:38 UTC | BORGWARNER INC BWA · Entity 3425 | GrantCommon Stock | 2,985 | $43.55 | $129,996.75 |
DisclosureSEC source: 0000908255-19-000043 · wf-form4_155734428475468.xml · nonDerivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,404.47 F1 · shares: The shares will vest 100% on the first anniversary of the grant date. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:50 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,708.158 | $49.89 | $185,000.00 |
DisclosureSEC source: 0000014272-19-000037 · wf-form4_154940339142108.xml · derivative · entry 1 SATO VICKI L · CIK 0001197020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,318.088 Underlying: Common Stock, $0.10 par value · 3,708.158 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.